Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 5th Preview)
-
FDA approval: first disease-modifying Alexander disease therapy
The FDA has approved Ionis Pharmaceuticals’ antisense therapy Zanvastro (zilganersen) for Alexander disease in pediatric and adult patients, marking the first disease-modifying treatment for the ultra-rare, progressive neurological disorder. The approval follows pivotal trial results showing stabilization of gait speed in treated patients compared with decline in the control arm, with supportive functional signals across younger age groups. Zanvastro is administered intrathecally at 50 mg on a quarterly basis and works by reducing production of GFAP (glial fibrillary acidic protein), the protein implicated in Alexander disease pathophysiology. Ionis will now move Zanvastro toward commercial availability, supported by a patient access and support program. The approval also gives Ionis a rare pediatric disease priority review voucher, underscoring regulators’ emphasis on expedited pathways for conditions with limited or no therapeutic options. The launch will be notable for being the company’s first wholly owned neurology product without a commercialization partner.
-
Phase 3 readouts: multiple myeloma T-cell engager etentamig posts survival benefit
AbbVie reported that its dual-acting bispecific antibody etentamig met a Phase 3 primary goal in relapsed or refractory multiple myeloma, improving outcomes versus standard therapy. In the study, etentamig reduced the risk of disease progression or death by 60% compared with the control arm, alongside improvements in response and progression-free survival. AbbVie also highlighted a potentially improved safety profile, with lower rates of serious immune-related adverse events associated with cytokine release syndrome and ICANS than seen with some comparable bispecifics. The company positioned the tolerability signal as a way to expand practical use beyond specialized centers. The program includes 421 trial participants and was unblinded after independent trial monitors detected a statistically significant difference at a planned interim checkpoint, with 393 evaluable patients analyzed at a mean follow-up of about 11 months.
-
Phase 3 setback: Novartis pelacarsen misses cardiovascular outcomes in HORIZON
Novartis said its experimental cardiovascular drug pelacarsen failed to reduce cardiovascular death or emergency events in a pivotal Phase 3 trial, the company announced. The study, HORIZON, tested the Ionis-partnered agent designed to lower Lp(a), a lipid-related biomarker strongly associated with cardiovascular risk. Earlier trials had shown that pelacarsen can sharply reduce Lp(a) levels, but the Phase 3 results did not translate into a statistically significant reduction in major cardiovascular endpoints versus placebo. The negative outcome represents a key read-through on whether lowering Lp(a) via this mechanism can deliver hard clinical benefit. The failure is a major negative for the Lp(a) targeting pipeline and increases scrutiny on how biomarker-lowering strategies are selected for late-stage testing.
-
Clinical pipeline funding: NeuShen lands $80M Series B for brain-health drugs
NeuShen Therapeutics, a Shanghai and Boston biotech led by a veteran transpacific drug developer, raised more than $80 million in a Series B financing to advance three clinical-stage brain-health programs. The funding supports continued development across its pipeline of central nervous system-targeted therapies. The deal signals continued investor appetite for late clinical-stage neuroscience assets with credible clinical pathways, even as funding conditions remain selective across the broader biotech market. NeuShen’s emphasis on brain-health aligns with ongoing demand for modalities that can address difficult-to-treat neurological diseases. For existing shareholders and future partners, the capital provides runway to push programs through upcoming trial milestones and potentially broaden the company’s partnering strategy for later-stage development.
-
Regulatory approvals: China clears Everest heart spray and Simcere RSV antibody
China’s National Medical Products Administration approved two new differentiated therapies aimed at lowering acute and seasonal disease burdens. Everest Medicines’ Cardamyst received clearance as a self-administered nasal spray for paroxysmal supraventricular tachycardia, while Simcere Pharmaceutical’s Yingmule was approved as a long-acting monoclonal antibody to prevent RSV-related lower respiratory tract infections in newborns and infants. Both approvals highlight a mix of home-use cardiovascular innovation and seasonal passive immunization designed to reduce severe respiratory outcomes. For Everest, Cardamyst becomes the company’s first innovative cardiovascular product in China; for Simcere, Yingmule expands its anti-infective portfolio and supports its commercialization structure. The authorizations also reflect ongoing regulatory prioritization of at-home delivery formats and preventive immunotherapies in pediatrics, where clinical benefit can be tightly linked to reduced hospitalization risk.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.